Karen Aiach, Lysogene CEO (RE(ACT) Discovery Institute)
November 21, 2022 07:33 AM ESTUpdated 08:01 AM
R&D
Cell/Gene Tx

Gene ther­a­py flunks PhII/III study, but for­mer Sarep­ta part­ner sees a path for­ward — if it can find the cash

Amber Tong

The de­vel­op­ment path for Lyso­gene’s gene ther­a­py for MPS II­IA has been a rocky one. Af­ter the FDA slapped a par­tial clin­i­cal hold on a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times